billS5383Event Saturday, August 8, 2026Analyzed

A bill to amend the Controlled Substances Act to schedule MGM-15 and MGM-16 as schedule I controlled substances, and to amend the controlled Substances Act to schedule synthetic 7-hydroxymitragynine, and Mitragynine Pseudoindoxyl, as a Schedule I above a specific threshold under the controlled substance act, and to expand enforcement actions against drug manufacturers and distributors of emerging synthetic opioids, commonly known as gas station heroin.

Neutral

Summary

S5383 is an early-stage bill to schedule specific synthetic opioids as Schedule I controlled substances and expand enforcement against manufacturers and distributors. No funding is authorized, and no publicly traded companies are directly named or clearly affected. The bill has no near-term market impact.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.S5383 is in early legislative stages with no funding or direct corporate beneficiaries.
  • 2.No publicly traded company is clearly impacted; any revenue effects are indirect and immaterial.
  • 3.Investors should not adjust positions based on this bill.

Market Implications

The bill has no near-term market implications. It is a scheduling and enforcement measure that does not authorize spending or directly affect any public company's revenue. Investors should ignore this signal.

Full Analysis

Senator Moreno introduced S5383 on August 8, 2026, which was read twice and referred to the Senate Judiciary Committee. The bill amends the Controlled Substances Act to add MGM-15, MGM-16, synthetic 7-hydroxymitragynine, and Mitragynine Pseudoindoxyl as Schedule I substances above a threshold, and expands enforcement actions against manufacturers and distributors of emerging synthetic opioids (gas station heroin). As a scheduling and enforcement bill, it does not authorize any spending. The legislative path is long: it must pass committee, the full Senate, the House, and be signed by the President. No companion bill or cosponsors exist. The bill's impact on public companies is negligible. Drug testing laboratories (e.g., $DGX, $LH) could see incremental demand for new test panels, but the link is indirect and the revenue impact would be immaterial relative to their total revenue. Addiction treatment providers (e.g., $ACHC, $HCA) might see a minor increase in patient volume if enforcement reduces supply, but the effect is speculative and years away. No ticker meets the confidence threshold for inclusion. The bill is a procedural step in drug policy, not a market-moving event.

Key Legislators

Sen. Moreno, Bernie [R-OH]

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderAug 6, 2026

Continuing to Protect the Meaning and Value of American Citizenship

This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.

Exec OrderAug 6, 2026

Ending Birth Tourism

This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.

proclamationJul 13, 2026

Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security

President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →